Business
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO, June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.\nJanssen Research & Development, LLC (Janssen)-sponsored study with therapeutics utilizing ENHANZE® technology:\nSubcutaneous daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis \nOral abstract session: Updated results from the Phase 3 ANDROMEDA study of DARZALEX FASPRO® in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of newly diagnosed AL amyloidosis (Abstract #8003). Bristol Myers Squibb-sponsored study with therapeutics utilizing ENHANZE® technology:\nCheckMate 8KX: Phase 1/2 multi-tumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20)\nPoster session: The first data on the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of subcutaneous nivolumab + rHuPH20 (Abstract #2575).Roche-sponsored study with therapeutics utilizing ENHANZE® technology:\nPotential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States\nPoster session: The aim of this study is to estimate the incremental difference in non-drug costs between PH FDC SC and PT IV for a typical patient receiving treatment for HER2-positive early breast cancer in Western Europe and the United States (Abstract #544).About HalozymeHalozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 500,000 patient lives via five commercialized products across more...